FY2025 · ended Dec 31, 2025 · Revenue $190,000, -19.1% YoY · Filed Mar 5, 2026
aTYR PHARMA INC (ATYR) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $190,000 and a net loss of $74.1 million. Free cash flow was -$62.1 million. As of Jun 30, 2026 it held $57.4 million in cash and investments and $11.3 million in total debt.
Revenue
$190,000
-19.1% vs prior year
Net income
$-74.12M
-15.8% vs prior year
Operating cash flow (TTM)
$-54.54M
+1.9% vs year-ago TTM
Free cash flow (TTM)
$-54.82M
+1.5% vs year-ago TTM
EPS
$-0.80
+7.0% vs prior year
Dividend per share
None
Shares outstanding
98.05M
+10.3% vs prior year
Net cash
$46.12M
as of Jun 30, 2026
Operating margin
-40856.3%
FY 2025
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- ATYR (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Diego, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1339970
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $190,000 | $235,000 | $353,000 | $10.4M | — |
| Operating income | -$77.6M | -$67.9M | -$54.9M | -$46.4M | -$34.0M |
| Net income | -$74.1M | -$64.0M | -$50.4M | -$45.3M | -$33.8M |
| Diluted EPS | -$0.80 | -$0.86 | -$0.94 | -$1.60 | — |
| Operating cash flow | -$62.0M | -$69.1M | -$33.2M | -$41.9M | -$33.1M |
| Free cash flow | -$62.1M | -$69.2M | -$37.4M | -$43.5M | -$33.3M |
| Total assets | $93.0M | $96.8M | $120.7M | $95.8M | $115.5M |
| Stockholders' equity | $67.5M | $70.0M | $90.7M | $71.5M | $109.3M |
| Cash and investments | $78.7M | $72.1M | $98.2M | $66.1M | $107.9M |
| Total debt | $12.0M | $13.3M | $15.4M | $14.3M | $1.4M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Nov 6, 2026 | Nov 6, 2026 |
| 10-Q | Quarterly report | Nov 6, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 5, 2026 | Nov 5, 2026 |
| 8-K |
Current report
Bylaw or fiscal year change
|
Oct 27, 2026 | Oct 27, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Oct 16, 2026 | Oct 16, 2026 |
| 8-K |
Current report
Other events
|
Sep 24, 2026 | Sep 24, 2026 |
All 755 aTYR PHARMA INC SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.